Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.19.1
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended
Mar. 11, 2019
Feb. 25, 2019
Jan. 18, 2019
May 31, 2018
Dec. 31, 2017
ADS [Member]          
Statement Line Items [Line Items]          
Aggregate ordinary shares       400,000 138,890
Subsequent Event [Member]          
Statement Line Items [Line Items]          
Aggregate ordinary shares     4,476,192    
Warrants to purchase shares     4,476,192    
Warrant exercise price $ 0.67   $ 1.30    
Aggregate purchase price     $ 2,350    
Sale of milestone description   The Company’s Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 3,000 in upfront and milestone payments payable with respect to the NASH indication.      
Subsequent Event [Member] | NIS [Member]          
Statement Line Items [Line Items]          
Warrant exercise price $ 2.344        
Grant of unlisted options exercisable 400,000        
Subsequent Event [Member] | ADS [Member] | Direct Offering [Member]          
Statement Line Items [Line Items]          
Sale of american depositary share     2,238,096    
Warrants to purchase shares     2,238,096